Abstract: A family of peptides with antioxidant and brightening activities is disclosed as well as cosmetic compositions having the peptides and cosmetic uses and methods of the peptides or cosmetic compositions.
Type:
Grant
Filed:
February 23, 2018
Date of Patent:
February 15, 2022
Assignee:
LIPOTRUE, S.L.
Inventors:
Ariadna Grau-Campistany, Silvia Pastor, Patricia Carulla, Juan Carlos Escudero
Abstract: The invention provides a method for combating biofilm, said method comprising contacting a biofilm with a composition comprising an effective amount of antimicrobial peptide biofilm enzyme combinations, preferably in the form of a fusion protein. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides a composition for use in the treatment or prevention of a biofilm in a subject, particularly in the oral cavity.
Type:
Grant
Filed:
May 12, 2017
Date of Patent:
February 15, 2022
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Abstract: Provided are: a peptide for regulating reactivity to a serotonin reuptake inhibitor-based antidepressant; a vector and a pharmaceutical composition for preventing or treating depression, which comprise same; a method for screening for an antidepressant by evaluating the activity of mossy cells; and the like.
Type:
Grant
Filed:
July 26, 2019
Date of Patent:
January 25, 2022
Assignee:
DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventors:
Yong Seok Oh, Seo Jin Oh, Jin Hyuk Jang, Jeong Rak Park, Chang Hun Shin, Min Seok Jeong
Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.
Type:
Grant
Filed:
September 20, 2019
Date of Patent:
December 28, 2021
Assignee:
LEVO THERAPEUTICS, INC.
Inventors:
Christopher Bryant, Mark C. Manning, Ryan E. Holcomb
Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
Type:
Grant
Filed:
December 26, 2019
Date of Patent:
December 14, 2021
Assignee:
Adamas Pharma, LLC
Inventors:
Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
Abstract: The present invention relates to a peptide bound to CD44v6 and uses for inhibiting cancer metastasis using the same, and the peptide of the present invention specifically binds to CD44v6 and inhibits it, thereby inhibiting cancer cell migration and metastasis. The peptides of the present invention selected two peptides (v6Pep-1 and v6Pep-2) that bind well to cells with high expression of human CD44v6 protein using phage peptide display technology and it was confirmed that it interferes with the binding between c-Met and CD44v6 to inhibit cancer cell migration. The peptide of the present invention is relatively stable in serum and shows a high potential as an anticancer treatment agent that suppresses metastasis due to the progression and migration of cancer in the future.
Type:
Grant
Filed:
December 17, 2018
Date of Patent:
December 7, 2021
Assignee:
KYUNGPOOK NATIONAL, UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Abstract: Provided herein are beta-TCP binding sequences and chimeric polypeptides that include one or more beta-TCP binding sequences and a mammalian growth factor, compositions comprising any of these chimeric polypeptides (and optionally, beta-TCP), and methods of promoting bone or cartilage formulation, methods of replacing and/or repairing bone or cartilage, and methods of treating a bone fraction or bone loss that include administration of any of these compositions.
Abstract: A medical device, a method for preparation thereof, and use thereof are provided. The medical device comprises a thermoplastic elastomer that is composed of soft segments and hard segments. The method for preparing a medical device comprising a thermoplastic elastomer, comprises forming the thermoplastic elastomer into tubing or other shapes via extrusion, molding, or coating, assembling the tubing or other shapes with other parts including: cables, coils, coated cables, or coated coils, and bonding the tubing, cables, or coils with other components including: other tubing components, cables, coils, sleeves, electrical pulse generator, defibrillation shock generator, electrodes, sensors, or drug release components. The medical device is used for correcting cardiac rhythm, defibrillating, assisting hearts, sensing, stimulating neurological systems, gastrointestinal system, or skeletomuscular tissues or organs.
Abstract: This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.
Abstract: The present invention relates to a method of forming a peptide of Formula (I) (P1-Xaa1-Xaa2-P2) by ligating a first peptide of Formula (II) (P1-Xaa1-X—R, wherein X is O or S) to a second peptide of Formula (III) (Xaa1-Xaa2-P2) by enzymatically cleaving the bond between “Asx” and “X” in the first peptide of Formula (II) and ligating the fragment P1-Asx of the first peptide to the second peptide of Formula (III), wherein the enzymatic cleavage and ligation reaction is catalyzed by butelase 1 (SEQ ID NO: 1) and the peptide of Formula (I) is a depsipeptide, preferably a thiodepsipeptide. Further encompassed are peptides and dendrimeric peptide assemblies prepared using the presently disclosed method, as well as use of the dendrimeric peptide assemblies as a vaccine, medicament, or diagnostic agent, particularly as an antimicrobial agent.
Type:
Grant
Filed:
September 29, 2016
Date of Patent:
August 17, 2021
Assignee:
Nanyang Technological University
Inventors:
James P Tam, Kien Truc Giang Nguyen, Yuan Cao, Chuan Fa Liu
Abstract: A novel fibrinogen-based tissue adhesive patch is disclosed. The patch comprises a backing made from a non-permeable biocompatible polymer film into which a fibrinogen-based sealant is incorporated. In preferred embodiments of the invention, the biocompatible polymer film comprises units of a biocompatible block copolymer such as a polyethylene glycol-polycaprolactone-DL-lactide copolymer connected by urethane linkages, and the fibrinogen-based sealant comprises fibrinogen, thrombin, and CaCl2. In contrast to similar patches known in the art, the polymer backing serves to seal the tissue to which the patch is applied, and the sealant acts only to bind the patch to the affected tissue. The patch does not include any mesh, woven, or non-woven component. Methods of production and use of the patch are also disclosed.
Type:
Grant
Filed:
July 23, 2018
Date of Patent:
July 27, 2021
Assignee:
SEALANTIUM MEDICAL LTD.
Inventors:
Orgad Laub, Daniel Cohn, Eran Cohen, Matthew Zarek
Abstract: A method of bioactive molecule delivery includes providing a first aqueous medium comprising native graphene oxide and a second aqueous medium comprising a bioactive molecular component that includes Gd(III)-labeled molecules; mixing said first and second media to form a mixture thereof; co-incubating the mixture for a first period of time for coupling said molecular component on a surface of said native graphene oxide, to provide a co-incubation product; and contacting a cellular medium with said co-incubation product for a second period of time for cellular delivery of said bioactive molecular component.
Type:
Grant
Filed:
August 30, 2016
Date of Patent:
May 4, 2021
Assignee:
NORTHWESTERN UNIVERSITY
Inventors:
Mark C. Hersam, Thomas J. Meade, Hsiang-Hua Hung
Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.
Type:
Grant
Filed:
June 26, 2019
Date of Patent:
April 27, 2021
Assignee:
EVOLVED BY NATURE, INC.
Inventors:
Gregory H. Altman, Rebecca L. Lacouture, Rachel Lee Dow, Rachel M. Lind, Dylan S. Haas
Abstract: A resilient resorbable chemically crosslinked collagen sponge for promoting soft tissue volume augmentation in the oral region, comprising 60-96% (w/w) collagen and 4-40% (w/w) elastin, which shows by mercury intrusion porosimetry interconnected pores with a median pore diameter between 50 and 90 ?m and at least 80% porosity with a pore diameter more than 10 ?m, an onset temperature of 45 to 57° C. and a density in dry state from 50 to 65 mg/cm3. A process for preparing a resilient resorbable chemically crosslinked collagen sponge. A method of using a resilient resorbable chemically crosslinked collagen sponge as an implant in the oral cavity for soft tissue volume augmentation.
Type:
Grant
Filed:
March 26, 2019
Date of Patent:
April 27, 2021
Assignee:
Geistlich Pharma
Inventors:
Cornel Imhof, Lothar Schloesser, Niklaus Stiefel, Martin Wuest
Abstract: Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).
Type:
Grant
Filed:
March 27, 2019
Date of Patent:
June 22, 2021
Assignee:
University of Miami
Inventors:
Eckhard R. Podack, Taylor H. Schreiber, Samia Q. Khan
Abstract: The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.
Type:
Grant
Filed:
April 17, 2019
Date of Patent:
September 14, 2021
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Daniel L. Flynn, Michael D. Kaufman, Peter A. Petillo
Abstract: A vector production system is provided. The system comprises recombinant cells designed to encode at least a first recombinase under the control of an inducible promoter and the cells include an expression vector encoding a nucleic acid of interest within the regulatory elements of the expression vector which are flanked on either side by a target sequence for at least the first recombinase. The vector production system provides an efficient one-step process for producing linear or circular covalently closed vectors that incorporate a nucleic acid sequence of interest.
Abstract: The present invention provides nucleic acid amplification systems and methods that desirably reduce or eliminate false positive amplification signals resulting from contaminating biological material, e.g., nucleic acid, that may be present in one or more reagents used in an amplification reaction and/or that may be present in the environment in which an amplification reaction is performed. The invention offers the further advantage of requiring less stringent purification and/or sterility efforts than conventionally needed in order to ensure that enzymes and other reagents used in amplification reactions, and the environment in which an amplification reaction is performed, are free of bacterial or other nucleic acid contamination that may yield false positive results.
Type:
Grant
Filed:
April 29, 2019
Date of Patent:
February 1, 2022
Assignee:
GEN-PROBE INCORPORATED
Inventors:
Michael M. Becker, Kristin W. Livezey, Wai-Chung Lam